Valeant Pharmaceuticals said it planned to improve its nearly $46 billion takeover offer for U.S. firm Allergan to show its commitment to completing the deal, just a day after the latter formally rejected its unsolicited bid. "We are prepared to pay a full and fair price, but consistent with our track record, we will remain financially disciplined," said Valeant Chairman and CEO Michael Pearson in a letter to Allergan shareholders.

Full Story:

Related Summaries